Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Work is ongoing to recover UK clinical research capacity and capabililty post COVID-19 pandemic (https://sites.google.com/nihr.ac.uk/thefutureofukclinicalresearch/home), but many of the barriers investigators faced pre-pandemic persist. Taking a more patient-centred approach to reform may help apply lessons learned during the pandemic and facilitate ‘building back better’.
In an attempt to overcome resistance to immune checkpoint inhibitors (ICI), an ever-increasing number of trials are exploring combination treatment approaches. Outcomes of a novel ICI doublet presented by Desai and colleagues are discussed along with emerging novel strategies and a view to future ongoing rational trial design maximising patient benefit.